Mesenchymal Stem Cells and Uses Therefor

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

1 . A method of reducing inflammation in a human, comprising the step of systemically administering to the human a suspension of cells in an amount effective to reduce inflammation, wherein the cells are allogeneic mesenchymal stem cells. 
     
     
         2 . A method of reducing production or secretion of a pro-inflammatory cytokine in a human, comprising the step of administering to the human a suspension of cells in an amount effective to reduce production or secretion of the pro-inflammatory cytokine, wherein the cells are allogeneic mesenchymal stem cells. 
     
     
         3 . The method of  claim 2 , wherein the pro-inflammatory cytokine is tumor necrosis factor alpha, interferon gamma, or interleukin-17. 
     
     
         4 . A method of increasing production or secretion of an anti-inflammatory cytokine in a human, comprising the step of administering to the human a suspension of cells in an amount effective to increase production or secretion of the anti-inflammatory cytokine, wherein the cells are allogeneic mesenchymal stem cells. 
     
     
         5 . The method of  claim 4 , wherein the anti-inflammatory cytokine is interleukin-4 or interleukin-10. 
     
     
         6 . The method of  claim 1 ,  2 , or  4 , wherein the suspension is administered intravenously or intraarterially. 
     
     
         7 . The method of  claim 1 ,  2 , or  4 , wherein the suspension further comprises an acceptable pharmaceutical carrier. 
     
     
         8 . The method of  claim 7 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection. 
     
     
         9 . The method of  claim 1 ,  2 , or  4 , wherein the mesenchymal stem cells express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         10 . The method of  claim 1 ,  2 , or  4 , wherein the mesenchymal stem cells are capable of binding to an antibody selected from the group consisting of an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, and an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745. 
     
     
         11 . The method of  claim 1 ,  2 , or  4 , wherein the suspension is administered in an amount of from about 1×10 5  cells/kg to about 1×10 7  cells/kg. 
     
     
         12 . The method of  claim 1 ,  2 , or  4 , wherein the suspension is administered in an amount of from about 1×10 6  cells/kg to about 5×10 6  cells/kg. 
     
     
         13 . The method of  claim 1 ,  2 , or  4 , wherein the suspension is administered in an amount of about 3×10 6  cells/kg.